Scientists say Ozempic’s active ingredient helped old female mice live longer and age more slowly, beating calorie cutting on several health measures.
Story Snapshot
- A Nature study reports semaglutide extended median lifespan in older female mice from 742 to 834 days.
- Treated mice showed better physical function and signs of slower aging at the cellular level.
- Researchers say benefits went beyond reduced food intake, a known path to longer life in animals.
- The authors stress the work does not show these drugs extend human lifespan.
What The New Study Found In Older Mice
Researchers reported in Nature that female mice started on semaglutide late in life lived longer. Median lifespan rose from 742 days in control mice to 834 days in treated mice, a gain of more than 12 percent. The team began daily injections when mice were about 20 months old, which is late life for this strain. The study tied the drug to stronger physical performance and healthier blood sugar. The authors said the gains suggest slower aging, not only weight loss.
NIH study: Ozempic slows aging in mice
Read the full story: https://t.co/f5uH19Usdh
NIH-funded UC Berkeley research finds semaglutide extended median lifespan by nearly 100 days in older mice while improving cognition, muscle function, and inflammation markers.#semaglutide… pic.twitter.com/zGtYEwmHLz
— wondernews.now (@wondernews_now) September 12, 2026
The work was led by Danica Chen at the University of California, Berkeley, and funded by the National Institute on Aging. Berkeley’s own summary said mice given the drug until death lived about 100 days longer on average than controls, matching the median shift in the paper. Each treatment group held roughly 20 animals. Independent science coverage reported the same survival window and the same delays in several known markers of aging in tissue and blood.
How Semaglutide May Do More Than Cut Calories
Semaglutide reduced how much the mice ate, and eating less is already known to extend life in animals. Yet the data suggest the drug improved functions beyond what reduced food intake explains, including memory and glucose control in specific tests. Earlier research shows glucagon-like peptide-1 signaling can reverse aging-like patterns in brain support cells, pointing to broader effects on inflammation and stress responses. That pathway could help explain the body-wide resilience seen in treated mice.
The drug tested here is the same class millions already use for diabetes and weight loss, which is exactly why the authors drew a hard line around their result. They wrote that the findings “do not show that Ozempic, Wegovy, or other GLP-1 drugs can extend human lifespan,” and that further clinical research is needed to learn whether effects seen in mice carry over to people. The result is late-life benefit in female mice, not a cure for aging.
Why This Matters For People And Policy
The finding touches a shared public concern: health costs keep rising while many feel the system misses root causes of disease. If a widely used drug class also slows parts of aging biology, it could shift how we think about prevention. That could mean longer working years, fewer hospital stays, and pressure to study aging directly, not one disease at a time. Mouse results cannot prove human lifespan effects, but they do justify larger and longer human trials.
The study also raises questions that unite both sides of the aisle. Who will fund careful trials that measure strength, memory, and independence over years, not months? How will insurers decide coverage if benefits stack up outside diabetes and obesity? Voters see drug and insurance giants shape the rules while families struggle to afford care. Clear, public data on risks, doses, and who benefits most would help avoid hype and protect patients as research moves forward.
Sources:
sciencedaily.com, vcresearch.berkeley.edu, lifespan.io